Skip to main content
TKNO
NASDAQ Life Sciences

Alpha Teknova Reports Improved Q4 & Full Year 2025 Results, Provides Positive 2026 Revenue Guidance

Analysis by Wiseek.ai
Sentiment info
Positive
Importance info
7
Price
$2.28
Mkt Cap
$122.047M
52W Low
$1.91
52W High
$7.48
Market data snapshot near publication time

summarizeSummary

Alpha Teknova, Inc. announced improved financial results for Q4 and full year 2025, including reduced losses and better cash flow, alongside 2026 revenue guidance and a target for Adjusted EBITDA positivity by late 2027.


check_boxKey Events

  • Full Year 2025 Revenue Growth

    Total revenue for the full year 2025 reached $40.5 million, marking a 7% increase year-over-year from $37.7 million in 2024, aligning with previous guidance.

  • Improved Profitability Metrics

    Net loss for 2025 significantly improved to negative $17.3 million (negative $0.32 per diluted share) from negative $26.7 million in 2024. Adjusted EBITDA also improved to negative $6.7 million from negative $14.5 million in 2024.

  • Reduced Cash Outflow

    Free Cash Flow for the full year 2025 was negative $9.8 million, a substantial improvement from negative $13.5 million in 2024 and better than the company's target of less than negative $12 million.

  • 2026 Revenue Guidance Provided

    The company anticipates total revenue between $42 million and $44 million for the fiscal year ending December 31, 2026.


auto_awesomeAnalysis

Alpha Teknova, Inc. reported a significant improvement in its financial performance for both the fourth quarter and full year 2025, with reduced net losses and substantially better Adjusted EBITDA and Free Cash Flow compared to the prior year. The company's 2026 revenue guidance indicates continued growth, and management's strategic focus on increased commercial investment aims to achieve Adjusted EBITDA positivity by the end of 2027. These results suggest a positive trajectory for the company, addressing prior concerns about profitability and cash burn, and providing a clearer path forward for investors.

At the time of this filing, TKNO was trading at $2.28 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $122M. The 52-week trading range was $1.91 to $7.48. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed TKNO - Latest Insights

TKNO
Apr 21, 2026, 5:22 PM EDT
Filing Type: DEF 14A
Importance Score:
8
TKNO
Mar 02, 2026, 5:15 PM EST
Source: Wiseek News
Importance Score:
7
TKNO
Mar 02, 2026, 5:10 PM EST
Filing Type: 10-K
Importance Score:
8
TKNO
Feb 26, 2026, 4:08 PM EST
Filing Type: 8-K
Importance Score:
7